Nirmatrelvir/ritonavir can reduce COVID-19 severity when initiated within five days of symptom onset but the optimal timing within this window is unknown. Here, the authors emulate a randomised trial using electronic health records from Hong Kong and find evidence for a benefit of early treatment initiation.
All Keywords
【저자키워드】 SARS-CoV-2, viral infection, Epidemiology, Outcomes research,
【저자키워드】 SARS-CoV-2, viral infection, Epidemiology, Outcomes research,